Trial Profile
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 10 Apr 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Colon cancer
- Focus Therapeutic Use
- Acronyms ATOMIC
- 03 Apr 2024 Planned End Date changed from 2 Apr 2024 to 2 Apr 2025.
- 03 Apr 2024 Planned primary completion date changed from 2 Apr 2024 to 2 Apr 2025.
- 18 Jan 2023 Status changed from recruiting to active, no longer recruiting.